Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer

被引:15
|
作者
Rajpara, Raj S.
Schreibmann, Eduard
Fox, Tim
Stapleford, Liza J.
Beitler, Jonathan J.
Curran, Walter J.
Higgins, Kristin A. [1 ]
机构
[1] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA
来源
RADIATION ONCOLOGY | 2014年 / 9卷
关键词
Lung cancer; Locally advanced; Locoregional failure; PET/CT; Radiation; Chemotherapy; STANDARDIZED UPTAKE VALUE; PHASE-III; CONCURRENT CHEMOTHERAPY; FDG-PET; TRIAL; RADIOTHERAPY; INDUCTION; SURVIVAL; THERAPY; DISEASE;
D O I
10.1186/1748-717X-9-187
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Locoregional tumor failure (LRF) after definitive chemoradiation for patients with stage III NSCLC remains unacceptably high. This analysis sought to further define where LRF occurs relative to radiation dose received and pre-treatment PET scan-defined maximum standard uptake value (SUVmax). Methods: This was a retrospective study analyzing patients with stage III NSCLC treated with definitive radiation between 2006 and 2011. LRF was defined as failure within the ipsilateral lung, hilum or mediastinum. The CT simulation scan with the radiation dose distribution was registered to the CT or PET/CT documenting LRF. The region of LRF was contoured, and the dose to 95% of the volume (D95) of LRF was extracted. The pre-treatment SUVmax was also extracted for the anatomic region of LRF. Results: Sixty-one patients were identified. Median follow-up time was 19.1 months (range 2.37-76.33). Seventy four percent of patients were treated with 3-D conformal technique (3DCRT), 15% were treated with Intensity Modulated Radiotherapy (IMRT), and 11% were treated with a combination of 3DCRT and IMRT. Median prescribed radiation dose for all patients was 66 Gy (39.6-74). Concurrent chemotherapy was delivered in 90% of patients. Twenty-two patients (36%) developed a LRF, with a total of 39 anatomic regions of LRF identified. Median time to LRF was 11.4 months (3.5-44.6). Failures were distributed as follows: 36% were in-field failures, 27% were out-of-field failures, 18% were in-field and out-of-field failures, and 18% were in-field and marginal (recurrences within the field edge) failures. There were no isolated marginal failures. Of the patients that developed a LRF, 73% developed a LRF with an in-field component. Sixty-two percent of LRFs were nodal. The median pre-treatment SUVmax for the anatomic region of LRF for patients with an in-field failure was 13. The median D95 of in-field LRF was 63 Gy. Conclusions: LRF after definitive chemoradiation are comprised primarily of in-field failures, though out-of field failures are not insignificant. Marginal failures are rare, indicating field margins are appropriate. Although radiation dose escalation to standard radiation fields has not yielded success, using PET parameters to define high-risk regions remains worthy of further investigation.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer
    Raj S Rajpara
    Eduard Schreibmann
    Tim Fox
    Liza J Stapleford
    Jonathan J Beitler
    Walter J Curran
    Kristin A Higgins
    Radiation Oncology, 9
  • [2] Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy
    Garg, Shalini
    Gielda, Benjamin T.
    Kiel, Krystyna
    Turian, Julius V.
    Fidler, Mary Jo
    Batus, Marta
    Bonomi, Philip
    Sher, David J.
    PRACTICAL RADIATION ONCOLOGY, 2014, 4 (05) : 342 - 348
  • [3] Patterns of Locoregional Failure in Stage III Non-Small Cell Lung Cancer Managed With Definitive Chemoradiation Therapy
    Garg, S.
    Gielda, B.
    Turian, J.
    Bonomi, P.
    Sher, D. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S516 - S516
  • [4] Locoregional failure in locally advanced non-small cell lung cancer after definitive radiotherapy
    Jouglar, E.
    Isnardi, V.
    Goulon, D.
    Segura-Ferlay, C.
    Ayadi, M.
    Dupuy, C.
    Mahe, M. A.
    Claude, L.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S321 - S321
  • [5] Radiation and chemotherapy for patients with stage III non-small cell lung cancer
    Green, MR
    Lima, CMR
    Sherman, CA
    SEMINARS IN RADIATION ONCOLOGY, 2000, 10 (04) : 289 - 295
  • [6] Early Tumor Regression Impacts on Outcome in Stage III Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy
    Kanzaki, H.
    Kataoka, M.
    Nishijima, N.
    Nagasaki, K.
    Uwatsu, K.
    Nishikawa, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E447 - E448
  • [7] Radiation Dose to the Heart and Mortality in Patients Receiving Definitive Chemoradiation Therapy for Stage III Non-Small Cell Lung Cancer
    Zaki, M.
    Xu, Y.
    Dominello, M. M.
    Dyson, G.
    Wozniak, A.
    Gadgeel, S.
    Paximadis, P. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S200 - S200
  • [8] Sublobar Resection Versus Definitive Radiation in Patients With Stage IA Non-Small Cell Lung Cancer
    Fernandez, Felix G.
    Crabtree, Traves D.
    Liu, Jingxia
    Meyers, Bryan F.
    ANNALS OF THORACIC SURGERY, 2012, 94 (02): : 354 - 361
  • [9] PROGNOSTIC FACTORS IN DEVELOPMENT OF BRAIN METASTASIS IN STAGE III NON-SMALL CELL LUNG CANCER PATIENTS AFTER DEFINITIVE TREATMENT
    Cetin, I. Alsan
    Cetinkaya, Z. Akgun
    Yumuk, P. F.
    Dane, F.
    Karauc, G.
    Sunnetci, N.
    Turhal, N. S.
    Atasoy, B. M.
    ANNALS OF ONCOLOGY, 2012, 23 : 394 - 394
  • [10] Predictors for pneumonitis for stage II-III non-small cell lung cancer after definitive radiotherapy
    Xu, Xiaohong
    He, Jian
    RADIOTHERAPY AND ONCOLOGY, 2024, 197 : S212 - S213